Health Care • Medical/Dental Instruments
$22.41 ▲ +0.58
(+2.66%)
MKT CAP: $1.00B • VOL: 950.3K
52W L $11 52W H $23
SIBN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $200.9M | $167.2M | $138.9M |
| YoY Revenue Growth % | +20.2% | +20.4% | — |
| Gross Profit | $159.9M | $132.1M | — |
| Gross Margin % | 79.6% | 79.0% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$22.3M | -$35.2M | -$46.9M |
| Operating Margin % | -11.1% | -21.1% | -33.8% |
| Net Income (GAAP) | -$18.9M | -$30.9M | -$43.3M |
| EBITDA (Normalized) | -$15.6M | -$26.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$675.0K | -$12.4M | -$18.7M |
| Capital Expenditures (CapEx) | $8.4M | $10.5M | — |
| Free Cash Flow (FCF) | -$9.1M | -$22.9M | -$18.7M |
| FCF Margin % | -4.5% | -13.7% | -13.5% |
| Return on Invested Capital (ROIC %) | -10.3% | -16.6% | — |
| Cash & Short-Term Equivalents | $42.2M | $34.9M | — |
| Total Debt (Short + Long Term) | $35.6M | $35.5M | — |
| Total Stockholders' Equity | $177.5M | $167.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR SIBN.